Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vaxart ( (VXRT) ) has provided an announcement.
On August 20, 2025, Vaxart, Inc. held a virtual fireside chat with stockholders to discuss a proposed reverse stock split and its implications for the company’s NASDAQ listing. The management emphasized the importance of maintaining a NASDAQ listing for increased visibility, liquidity, and access to capital, which are crucial for advancing their vaccine development programs. The reverse stock split is seen as a strategic move to enhance the company’s market position and protect stockholder investments, with advisory firms ISS and Glass Lewis recommending support for the proposal.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s overall stock score reflects significant financial challenges, including ongoing losses and negative cash flows, which are the most impactful factors. Technical analysis suggests bearish momentum, while valuation concerns persist due to a negative P/E ratio. Despite these issues, recent corporate events and earnings call highlights show potential for future growth, albeit with notable risks.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart, Inc. operates in the biotechnology industry, focusing on the development of oral pill vaccine candidates. The company’s primary market focus is on creating vaccines for infections such as norovirus, COVID-19, and avian flu, which offer potential advantages over traditional needle-based vaccines.
Average Trading Volume: 4,678,350
Technical Sentiment Signal: Sell
Current Market Cap: $84.13M
Learn more about VXRT stock on TipRanks’ Stock Analysis page.